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BACKGROUND
Patients who are hospitalized for medical illness remain at risk for venous throm-
boembolism after discharge, but the role of extended thromboprophylaxis in the 
treatment of such patients is a subject of controversy.
METHODS
In this randomized, double-blind trial, medically ill patients who were at increased 
risk for venous thromboembolism on the basis of a modified International Medi-
cal Prevention Registry on Venous Thromboembolism (IMPROVE) score of 4 or 
higher (scores range from 0 to 10, with higher scores indicating a higher risk of 
venous thromboembolism) or a score of 2 or 3 plus a plasma d-dimer level of more 
than twice the upper limit of the normal range (defined according to local labora-
tory criteria) were assigned at hospital discharge to either once-daily rivaroxaban 
at a dose of 10 mg (with the dose adjusted for renal insufficiency) or placebo for 
45 days. The primary efficacy outcome was a composite of symptomatic venous 
thromboembolism or death due to venous thromboembolism. The principal safety 
outcome was major bleeding.
RESULTS
Of the 12,024 patients who underwent randomization, 12,019 were included in the 
intention-to-treat analysis. The primary efficacy outcome occurred in 50 of 6007 
patients (0.83%) who were given rivaroxaban and in 66 of 6012 patients (1.10%) 
who were given placebo (hazard ratio, 0.76; 95% confidence interval [CI], 0.52 to 
1.09; P = 0.14). The prespecified secondary outcome of symptomatic nonfatal ve-
nous thromboembolism occurred in 0.18% of patients in the rivaroxaban group 
and 0.42% of patients in the placebo group (hazard ratio, 0.44; 95% CI, 0.22 to 
0.89). Major bleeding occurred in 17 of 5982 patients (0.28%) in the rivaroxaban 
group and in 9 of 5980 patients (0.15%) in the placebo group (hazard ratio, 1.88; 
95% CI, 0.84 to 4.23).
CONCLUSIONS
Rivaroxaban, given to medical patients for 45 days after hospital discharge, was not 
associated with a significantly lower risk of symptomatic venous thromboembolism 
and death due to venous thromboembolism than placebo. The incidence of major 
bleeding was low. (Funded by Janssen Research and Development; MARINER 
ClinicalTrials.gov number, NCT02111564.)
A BS TR AC T
Rivaroxaban for Thromboprophylaxis after 
Hospitalization for Medical Illness
Alex C. Spyropoulos, M.D., Walter Ageno, M.D., Gregory W. Albers, M.D., 
C. Gregory Elliott, M.D., Jonathan L. Halperin, M.D., William R. Hiatt, M.D., 
Gregory A. Maynard, M.D., P. Gabriel Steg, M.D., Jeffrey I. Weitz, M.D., 
Eunyoung Suh, Ph.D., Theodore E. Spiro, M.D., Elliot S. Barnathan, M.D.,  
and Gary E. Raskob, Ph.D., for the MARINER Investigators* 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF SZEGED on February 11, 2020. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;12 nejm.org September 20, 2018 1119
Rivaroxaban for Thromboprophylaxis after Hospitalization
Patients who are hospitalized for acute medical illnesses, such as heart fail-ure, respiratory insufficiency, stroke, and 
infectious or inflammatory diseases, are at in-
creased risk for venous thromboembolism.1 Vali-
dated risk scores that include additional factors, 
such as a lack of mobility, advanced age, cancer, 
previous venous thromboembolism, and elevated 
d-dimer levels, aid in the identification of pa-
tients who are at risk for symptomatic venous 
thromboembolism.2-4
Anticoagulant prophylaxis reduces the risk of 
in-hospital venous thromboembolism by 50 to 
60% but is rarely continued after discharge in 
accordance with current guidelines.5,6 The risk 
of symptomatic venous thromboembolism, includ-
ing fatal pulmonary embolism, in this popula-
tion persists for 6 weeks or more after hospital 
discharge.2,7 However, studies of extended throm-
boprophylaxis have shown either excess major 
bleeding or a benefit that is based mainly on 
reducing the risk of asymptomatic deep-vein 
thrombosis.8-11 Therefore, we performed a ran-
domized trial of rivaroxaban treatment initiated 
at discharge and given for 45 days to medically 
ill patients who were at risk for venous thrombo-
embolism. In our trial, we focused only on symp-
tomatic or fatal events.12
Me thods
Trial Design and Oversight
The Medically Ill Patient Assessment of Rivaroxa-
ban versus Placebo in Reducing Post-Discharge 
Venous Thrombo-Embolism Risk (MARINER) 
trial was a randomized, double-blind, placebo-
controlled, multinational clinical trial. The ratio-
nale and design of the trial have been reported 
previously.12 An executive committee in collabo-
ration with the sponsor (Janssen Research and 
Development) was responsible for the trial de-
sign, protocol, and oversight and served as the 
writing committee. The institutional review board 
or ethics committee at each of the 671 partici-
pating centers approved the protocol.
Coordination of study committees and support 
for trial execution were provided by an academic 
research organization (CPC Clinical Research), 
Worldwide Clinical Trials, and the academic 
leadership of the Antithrombotic Trials Leader-
ship and Steering (ATLAS) Group. The data were 
collected by a contract research organization 
(Parexel) that was paid by the sponsor. An inde-
pendent data and safety monitoring committee 
periodically reviewed trial outcomes and adverse 
events. The sponsor performed the statistical 
analysis in collaboration with the executive com-
mittee. The members of this committee, which 
included the authors, wrote all drafts of the 
manuscript and vouch for the accuracy and com-
pleteness of the data and analyses and for the 
fidelity of the trial to the protocol, which is 
available with the full text of this article at 
NEJM.org.
Patients
Patients were eligible for participation in the 
trial if they were 40 years of age or older and had 
been hospitalized for at least 3 and not more 
than 10 consecutive days with one of the follow-
ing conditions: heart failure with a left ventricu-
lar ejection fraction of 45% or less, acute respi-
ratory insufficiency or exacerbation of chronic 
obstructive pulmonary disease, acute ischemic 
stroke, or acute infectious or inflammatory dis-
ease, including rheumatic diseases. Eligible pa-
tients also had to have additional risk factors for 
venous thromboembolism, as indicated by a total 
modified International Medical Prevention Reg-
istry on Venous Thromboembolism (IMPROVE) 
risk score of 4 or higher (scores range from 0 to 
10, with higher scores indicating a higher risk of 
venous thromboembolism; minimal clinically im-
portant difference, 2) or a risk score of 2 or 3 plus 
a plasma d-dimer level of more than twice the 
upper limit of the normal range, with d-dimer 
measured locally and the normal range defined 
according to local laboratory criteria. Eligible 
 patients must also have received thromboprophy-
laxis with low-molecular-weight heparin or unfrac-
tionated heparin during the index hospitalization.
Patients were excluded if they had a condition 
that was being treated with anticoagulant or dual 
antiplatelet therapy or if they had active cancer, a 
history of recent bleeding (within 3 months) or a 
high risk of bleeding, or other contraindications 
to rivaroxaban. The full list of inclusion and ex-
clusion criteria and the criteria for the modified 
IMPROVE risk score2 are provided in Table S1 in the 
Supplementary Appendix, available at NEJM.org. 
All the patients provided written informed consent.
Trial Regimen and Follow-up
Patients were randomly assigned in a 1:1 ratio to 
receive either rivaroxaban or placebo. Randomiza-
tion was performed on the day of discharge 
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from the hospital or the next day, with the use 
of an interactive Web-based system, with strati-
fication according to country and creatinine 
clearance (≥30 and <50 ml per minute or ≥50 ml 
per minute). Randomization was balanced in per-
muted blocks of four. Patients were counseled 
about and instructed to promptly report symp-
toms or signs associated with deep-vein throm-
bosis, pulmonary embolism, and bleeding.
The rivaroxaban regimen was 10 mg once 
daily for patients with a creatinine clearance of 
at least 50 ml per minute or 7.5 mg once daily 
for patients with a creatinine clearance of at 
least 30 but less than 50 ml per minute. The first 
dose of rivaroxaban or placebo was given as soon 
as possible after randomization and not later 
than the next day. The trial agent was taken with 
or without food for 45 days. This duration was 
chosen because previous studies had shown that 
approximately 75% of post–hospital discharge 
venous thromboembolic events occur by 45 days 
after discharge.2,7
All the patients were contacted at approxi-
mately 7 days (range, 5 to 12), 21 days (range, 18 
to 28), and 45 days (range, 45 to 49) after ran-
domization, regardless of whether they contin-
ued to take rivaroxaban or placebo. At each 
contact, a review for suspected outcome events 
and assessment of symptoms, consisting of script-
ed questions (see the Supplementary Appendix), 
was completed. Counseling about the symptoms 
and signs of deep-vein thrombosis, pulmonary 
embolism, and bleeding was repeated, and data 
on adverse events and concomitant medications 
were collected. All the patients were contacted 
for safety follow-up on approximately day 75 
(range, 70 to 80).
Outcome Measures
The primary efficacy outcome was the compos-
ite of any symptomatic venous thromboembolism 
(i.e., deep-vein thrombosis in the legs or nonfatal 
pulmonary embolism) or death related to venous 
thromboembolism (i.e., death due to pulmonary 
embolism or death in which pulmonary embo-
lism could not be ruled out as the cause). The 
prespecified secondary efficacy outcomes were 
the two components of the primary outcome — 
symptomatic nonfatal venous thromboembolism 
and death related to venous thromboembolism 
— analyzed separately; the composite of nonfatal 
symptomatic venous thromboembolism or death 
from any cause; the composite of nonfatal symp-
tomatic venous thromboembolism, myocardial 
infarction, nonhemorrhagic stroke, or cardiovas-
cular death (death due to a known cardiovascu-
lar cause or death in which a cardiovascular 
cause, including pulmonary embolism, could not 
be ruled out); and death from any cause.
The principal safety outcome was major bleed-
ing. Other safety outcomes were nonmajor clini-
cally relevant bleeding, other bleeding, and ad-
verse events.
Major bleeding was defined as overt bleeding 
associated with a decrease in the hemoglobin 
level of 2 g per deciliter or more, bleeding that 
led to transfusion of 2 or more units of packed 
red cells or whole blood, bleeding that occurred 
in a critical site (i.e., intracranial, intraspinal, in-
traocular, pericardial, intraarticular, intramuscu-
lar with compartment syndrome, or retroperito-
neal), or fatal bleeding.13 Nonmajor clinically 
relevant bleeding was defined as overt bleeding 
that did not meet the criteria for major bleeding 
but was associated with medical intervention, un-
scheduled contact (visit or telephone call) with a 
physician, temporary cessation of the trial regi-
men, or pain or impairment of activities of daily 
life.12 Other bleeding was defined as any other 
overt bleeding that did not meet the criteria for 
major or nonmajor clinically relevant bleeding.
A clinical events committee, the members of 
which were unaware of the trial-group assign-
ments, adjudicated all suspected episodes of ve-
nous thromboembolism, bleeding, myocardial in-
farction, and stroke and all deaths, with the use 
of prespecified criteria. Death was adjudicated 
as being caused by pulmonary embolism, bleed-
ing, cardiovascular disease, or other causes. Pul-
monary embolism was considered the cause of 
death if there was objective documentation that 
pulmonary embolism caused the death or if the 
death could not be attributed to another docu-
mented cause and pulmonary embolism could 
not be ruled out. The criteria for the adjudication 
of the outcomes are provided in Table S2 in the 
Supplementary Appendix.
Statistical Analysis
The trial hypothesis was that rivaroxaban would 
be superior to placebo for the prevention of the 
primary efficacy outcome.12 The sample size was 
event-driven, with a targeted total number of 
events of the primary efficacy outcome of 161, 
which was determined under an assumption of 
a 40% lower relative risk with rivaroxaban than 
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with placebo, a power of 90%, and a two-sided 
significance level of 0.05. We estimated that a 
total of approximately 8000 patients would be 
needed in order to observe 161 events, on the 
basis of an estimated incidence of 2.5% in the 
placebo group. We prespecified that randomiza-
tion could be stopped at approximately 9000 
patients for administrative reasons even if the 
targeted 161 events had not been observed. Be-
cause the blinded incidence of pooled events was 
lower than we had estimated, the protocol was 
amended to increase the maximum number of 
patients enrolled to 12,000. For patients with 
multiple events, only the first was counted toward 
the determination of the size of the trial popula-
tion. One prespecified interim analysis was per-
formed to evaluate futility. Thus, an adjustment 
of the final significance level was not done.
All the efficacy analyses were performed with 
the intention-to-treat population and included all 
data and outcomes from randomization through 
day 45. The primary efficacy outcome was ana-
lyzed on the basis of the time from randomiza-
tion to the first occurrence of symptomatic 
venous thromboembolism or venous thrombo-
embolism–related death. The trial hypothesis was 
tested with a Cox proportional-hazards model, 
stratified according to creatinine clearance (≥30 
and <50 ml per minute or ≥50 ml per minute), 
with the randomly assigned regimen as the only 
covariate. Time-to-event curves were calculated 
with the Kaplan–Meier method.
If superiority of rivaroxaban for the prevention 
of the primary outcome was established, the 
secondary outcomes were to be tested sequen-
tially with the use of the same Cox proportional-
Figure 1. Randomization and Follow-up.
12,024 Patients underwent randomization
12,019 Patients were included in the
intention-to-treat analysis
2 Did not provide written informed consent
3 Did not have health-authority approval
6007 Were assigned to receive rivaroxaban 6012 Were assigned to receive placebo
25 Did not receive rivaroxaban 32 Did not receive placebo
11,962 Patients were included in
the safety analysis 
19 Had unknown outcome
status at day 45
1 Was lost to follow-up
18 Withdrew consent
24 Had unknown outcome
status at day 45
4 Were lost to follow-up
20 Withdrew consent
5982 Received rivaroxaban 5980 Received placebo
525 Discontinued rivaroxaban
prematurely
540 Discontinued placebo
prematurely
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hazards model, in the following hierarchical 
order, each at an alpha level of 0.05 (two-sided): 
venous thromboembolism–related death; symp-
tomatic venous thromboembolism; the compos-
ite of symptomatic venous thromboembolism or 
death from any cause; the composite of symptom-
atic venous thromboembolism, myocardial infarc-
tion, nonhemorrhagic stroke, or cardiovascular 
death; and death from any cause.
R esult s
Patients and Trial Regimen
From June 2014 through January 2018, a total of 
12,024 patients underwent randomization at 671 
centers in 36 countries. The flow of the patients 
through the trial is shown in Figure 1. The base-
line characteristics of the patients were similar 
in the two trial groups (Table 1). Permanent 
Characteristic
Rivaroxaban 
(N = 6007)
Placebo 
(N = 6012)
Mean age — yr 69.7 69.7
Age ≥75 yr — no. (%) 2154 (35.9) 2140 (35.6)
Male sex — no. (%) 3130 (52.1) 3154 (52.5)
White race — %† 5782 (96.3) 5808 (96.6)
Mean weight — kg 80.8 80.6
BMI‡ 29.0 28.8
Creatinine clearance — no. (%)
30 to <50 ml/min 1098 (18.3) 1099 (18.3)
≥50 ml/min 4909 (81.7) 4913 (81.7)
Reason for index hospitalization — no./total no. (%)
Heart failure 2435/6003 (40.6) 2399/6011 (39.9)
Respiratory insufficiency or exacerbation of COPD 1575/6003 (26.2) 1611/6011 (26.8)
Ischemic stroke 860/6003 (14.3) 866/6011 (14.4)
Infectious disease 1048/6003 (17.5) 1045/6011 (17.4)
Inflammatory disease 85/6003 (1.4) 90/6011 (1.5)
Mean duration of index hospitalization — days 6.7 6.7
Mean duration of in-hospital thromboprophylaxis — days 6.2 6.2
History of VTE — no. (%) 765 (12.7) 748 (12.4)
History of cancer — no. (%) 488 (8.1) 533 (8.9)
ICU or CCU stay — no. (%) 3260 (54.3) 3240 (53.9)
Current lower-limb paralysis or paresis — no. (%) 1115 (18.6) 1122 (18.7)
Modified IMPROVE VTE risk score — no. (%)§
2 2098 (34.9) 2151 (35.8)
3 1886 (31.4) 1779 (29.6)
≥4 2019 (33.6) 2075 (34.5)
d-Dimer level more than twice the upper limit of the normal 
range during index hospitalization — no. (%)¶
4226 (70.4) 4239 (70.5)
Aspirin use — no. (%) 3159 (52.6) 3046 (50.7)
Thienopyridine use — no. (%) 360 (6.0) 388 (6.5)
*  CCU denotes cardiac care unit, COPD chronic obstructive pulmonary disease, ICU intensive care unit, and VTE venous 
thromboembolism.
†  Race was reported by the patient.
‡  The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
§  Modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) risk scores range from  
0 to 10, with higher scores indicating a higher risk of venous thromboembolism (minimal clinically important differ-
ence, 2). Eleven patients had protocol violations: three patients in the rivaroxaban group and seven patients in the  
placebo group had a score of 1, and one patient in the rivaroxaban group had a score of 0.
¶  The normal range for d-dimer level was defined according to the local laboratory criteria.
Table 1. Characteristics of the Patients at Baseline.*
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discontinuation of rivaroxaban or placebo before 
45 days occurred in 8.9% of patients (Fig. 1). 
Temporary interruption of the regimen occurred 
in 176 patients (2.9%) assigned to rivaroxaban 
and in 183 patients (3.1%) assigned to placebo. 
Further details of treatment interruption and 
adherence are provided in Table S3 in the Sup-
plementary Appendix.
Efficacy Outcomes
The primary efficacy outcome of symptomatic 
venous thromboembolism or death related to ve-
nous thromboembolism occurred in 50 (0.83%) 
of 6007 patients in the rivaroxaban group and in 
66 (1.10%) of 6012 patients in the placebo group 
(hazard ratio, 0.76; 95% confidence interval [CI], 
0.52 to 1.09; P = 0.14) (Table 2). The difference in 
risk (rivaroxaban minus placebo) was −0.27 per-
centage points (95% CI, −0.61 to 0.08). The time 
to the occurrence of the primary outcome and 
its two components are shown in Figure 2.
The incidence of the primary efficacy outcome 
both overall and according to creatinine clear-
ance is shown in Table 2. Subgroup analyses for 
the primary efficacy outcome are shown in Figure 
S1 in the Supplementary Appendix. There were 
no significant interactions between subgroups 
and trial regimen.
Since superiority was not established in the 
primary efficacy analysis, the prespecified sec-
Outcome Rivaroxaban Placebo
Hazard Ratio 
(95% CI)†
no. of patients/total no. (%)
Primary efficacy outcome
Symptomatic VTE or VTE-related death 50/6007 (0.83) 66/6012 (1.10) 0.76 (0.52–1.09)‡
Creatinine clearance ≥50 ml/min, 10-mg dose 32/4909 (0.65) 48/4913 (0.98) 0.67 (0.43–1.04)
Creatinine clearance 30 to <50 ml/min, 7.5-mg dose 18/1098 (1.64) 18/1099 (1.64) 1.00 (0.52–1.92)
Secondary efficacy outcomes
VTE-related death 43/6007 (0.72) 46/6012 (0.77) 0.93 (0.62–1.42)
Symptomatic VTE 11/6007 (0.18) 25/6012 (0.42) 0.44 (0.22–0.89)
Symptomatic VTE or death from any cause 78/6007 (1.30) 107/6012 (1.78) 0.73 (0.54–0.97)
Symptomatic VTE, myocardial infarction, nonhemorrhagic 
stroke, or cardiovascular death
94/6007 (1.56) 120/6012 (2.00) 0.78 (0.60–1.02)
Death from any cause 71/6007 (1.18) 89/6012 (1.48) 0.80 (0.58–1.09)
Safety outcomes
Principal safety outcome: major bleeding 17/5982 (0.28) 9/5980 (0.15) 1.88 (0.84–4.23)
Creatinine clearance ≥50 ml/min, 10-mg dose 13/4890 (0.27) 9/4890 (0.18) 1.44 (0.62–3.37)
Creatinine clearance 30 to <50 ml/min, 7.5-mg dose 4/1092 (0.37) 0/1090 —
Criteria for major bleeding§
Hemoglobin decrease ≥2 g/dl 14/5982 (0.23) 6/5980 (0.10) 2.33 (0.89–6.05)
Transfusion of ≥2 units of packed red cells 11/5982 (0.18) 3/5980 (0.05) 3.66 (1.02–13.10)
Critical site 3/5982 (0.05) 2/5980 (0.03) 1.50 (0.25–8.97)
Fatal 2/5982 (0.03) 0/5980 —
Nonmajor clinically relevant bleeding 85/5982 (1.42) 51/5980 (0.85) 1.66 (1.17–2.35)
Other bleeding 54/5982 (0.90) 34/5980 (0.57) 1.59 (1.03–2.44)
*  Symptomatic VTE included deep-vein thrombosis in the legs and nonfatal pulmonary embolism. VTE-related death included death due to 
pulmonary embolism and death in which pulmonary embolism could not be ruled out as the cause. Cardiovascular death included death 
due to a known cardiovascular cause and death in which a cardiovascular cause, including pulmonary embolism, could not be ruled out.
†  The confidence intervals have not been adjusted, and inferences drawn from the intervals may not be reproducible.
‡  P = 0.14.
§  Some patients may have had more than one criterion.
Table 2. Clinical Outcomes during the 45-Day Treatment Phase.*
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ondary efficacy outcomes were assessed as explor-
atory analyses without adjustment for multiplic-
ity (Table 2). The time to the occurrence of each 
secondary outcome is shown in Figures 2 and 3.
Safety Outcomes
The principal safety outcome of major bleeding oc-
curred in 17 (0.28%) of 5982 patients in the riva-
roxaban group and in 9 (0.15%) of 5980 patients in 
the placebo group (hazard ratio, 1.88; 95% CI, 0.84 
to 4.23) (Table 2). The difference in risk (rivaroxa-
ban minus placebo) was 0.13 percentage points 
(95% CI, −0.03 to 0.30). The incidence of major 
bleeding according to the prespecified stratification 
based on creatinine clearance is shown in Table 2.
Subgroup analyses of major bleeding are 
shown in Figure S2 in the Supplementary Ap-
pendix. There were no significant interactions 
between the trial regimen and any subgroup 
variable, with the exception of the duration of 
the index hospitalization (P = 0.02) and in-hospi-
tal receipt of thromboprophylaxis (P = 0.03).
The incidence of clinically relevant nonmajor 
bleeding and other bleeding is shown in Table 2. 
Adverse events occurred with similar frequency 
in the rivaroxaban group and the placebo group 
(Tables S4, S5, and S6 in the Supplementary Ap-
pendix). A total of 160 patients died during the 
45-day treatment phase (71 in the rivaroxaban 
group and 89 in the placebo group). The causes 
of death are given in Table S7 in the Supplemen-
tary Appendix.
Discussion
In this trial involving medically ill patients, riva-
roxaban treatment that was started at the time 
of discharge from the hospital and continued for 
Figure 2. Kaplan–Meier Cumulative Event Rates  
for the Primary Efficacy Outcome and Its Components.
Shown are cumulative event rates for the composite 
outcome of symptomatic venous thromboembolism 
(VTE) (deep-vein thrombosis in the legs or nonfatal 
pulmonary embolism) or VTE-related death (death due 
to pulmonary embolism or death in which pulmonary 
embolism could not be ruled out as the cause) (Panel A), 
VTE-related death (Panel B), or symptomatic VTE 
(Panel C). In each panel, the inset shows the same 
data on an expanded y axis.Pa
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45 days was not associated with a significantly 
lower risk of the primary efficacy outcome of 
fatal or symptomatic venous thromboembolism 
than placebo. Therefore, all the subsequent ef-
ficacy analyses were exploratory. Although riva-
roxaban had no effect on the risk of venous 
thromboembolism–related death, it was associ-
ated with fewer symptomatic venous thrombo-
embolic events than placebo (risk difference, 
−0.24 percentage points). The incidence of major 
bleeding during treatment with rivaroxaban was 
low (0.28%; difference in risk vs. placebo, 0.13 
percentage points). These differences in risk sug-
gest that the number of patients needed to treat 
to prevent one symptomatic venous thromboem-
bolism event is 430, whereas the number needed 
to cause one major bleed is 856. Thus, although 
the benefit–risk decision for the individual patient 
is finely tuned, the implementation of extended 
thromboprophylaxis with appropriate selection 
of medically ill patients may reduce the health 
burden of nonfatal venous thromboembolism in 
this population.
The rationale for extended thromboprophy-
laxis is to prevent symptomatic deep-vein throm-
bosis and nonfatal and fatal pulmonary embo-
lism. Although we observed fewer symptomatic 
venous thromboembolic events with rivaroxaban 
than with placebo, no significant difference in 
venous thromboembolism–related mortality was 
observed. This observation is consistent with 
previously published trials of either short- or 
extended-duration prophylaxis in medical pa-
tients.8-11,14,15 The incidence of venous thrombo-
embolism–related death in the placebo group 
(0.77%) was higher than in trials of other direct 
oral anticoagulants.8,10 Most of these deaths were 
Figure 3. Kaplan–Meier Cumulative Event Rates  
for Composite Secondary Outcomes and Death  
from Any Cause.
Shown are cumulative event rates for the composite  
of symptomatic VTE or death from any cause (Panel A), 
the composite of symptomatic VTE, myocardial infarc-
tion, nonhemorrhagic stroke, or cardiovascular death 
(death due to a known cardiovascular cause or death  
in which a cardiovascular cause, including pulmonary 
embolism, could not be ruled out) (Panel B), and death 
from any cause (Panel C). In each panel, the inset shows 
the same data on an expanded y axis.
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sudden deaths in which pulmonary embolism 
could not be ruled out. The definition of venous 
thromboembolism–related death has varied 
across contemporary trials of extended throm-
boprophylaxis, and not all these trials have in-
cluded unexplained sudden death.8-10 The broader 
definition we used probably included some deaths 
that were not due to pulmonary embolism, 
which suggests that sudden death of unknown 
cause is not sufficiently specific for inclusion in 
the definition of fatal pulmonary embolism. Con-
versely, death from any cause includes death 
from thrombotic causes other than pulmonary 
embolism, which may explain why the compos-
ite outcome of symptomatic venous thromboem-
bolism and death from any cause was less fre-
quent in the rivaroxaban group.
In a previous trial involving medically ill pa-
tients, treatment with rivaroxaban at a dose of 
10 mg once daily started in the hospital and 
continued for 35 days reduced venous thrombo-
embolism but increased major bleeding.9 There-
fore, one goal of the current trial was to improve 
the safety of rivaroxaban in this population. 
This goal was achieved, as shown by lower inci-
dences of major bleeding than in the previous 
trial.9 Safety was enhanced by initiating riva-
roxaban at discharge, reducing the dose to 7.5 mg 
daily in patients with moderate renal impairment, 
and excluding patients who were identified as 
being at high risk for bleeding in the previous 
trial.9 The latter group included patients who 
had active cancer or gastrointestinal ulcer, bron-
chiectasis, or bleeding in the previous 3 months 
or were receiving dual antiplatelet therapy.
Patients with renal insufficiency have a higher 
incidence of thrombotic and bleeding events16,17 
than patients with normal renal function. In the 
previous trial,9 rivaroxaban at 10 mg daily was 
effective in patients with moderate renal insuf-
ficiency but was associated with increased bleed-
ing. In the current trial, the 7.5-mg daily dose of 
rivaroxaban given to patients with moderate re-
nal insufficiency was associated with a low inci-
dence of bleeding but not with a lower risk of 
the primary efficacy outcome than placebo. 
Similarly, the betrixaban dose-reduction strategy 
in medically ill patients showed less efficacy.10
This large trial of extended thromboprophy-
laxis in medically ill patients had strengths and 
limitations. The strengths included the use of 
symptomatic events as the primary efficacy out-
come, a low rate of loss to follow-up, and inde-
pendent event adjudication. Despite the use of a 
validated risk score and elevated d-dimer levels 
to enrich the rate of primary events, the inci-
dence in the placebo group was 1.1% rather than 
the expected 2.5%. Given the expected increase 
in d-dimer levels with age, it is possible that the 
cutoff we used for this assay (i.e., twice the up-
per limit of the normal range) led to the inclu-
sion of participants whose risk was lower than 
expected. The low incidence prompted the deci-
sion to stop enrollment before accumulation of 
the prespecified 161 patients with primary events. 
Other limitations included the difficulty in de-
fining venous thromboembolism–related death 
and the possible underdosing of patients with 
moderate renal impairment. In this trial, we did 
not record all the patients who were assessed for 
inclusion and from among whom the population 
that underwent randomization was selected. 
However, previous studies indicate that our in-
clusion criteria would represent approximately 25 
to 30% of all hospitalized medical patients.3,4,18
In conclusion, our trial did not show a sig-
nificant benefit of this rivaroxaban regimen 
started at hospital discharge with regard to the 
composite outcome of fatal or symptomatic ve-
nous thromboembolism in medically ill patients. 
Given the relatively low incidence of events de-
spite the enrichment strategy and the lack of effect 
on venous thromboembolism–related death, the 
usefulness of extended thromboprophylaxis re-
mains uncertain. Future studies should more ac-
curately identify deaths caused by thrombotic 
mechanisms and focus on the patients who are at 
highest risk and who may benefit from anticoagu-
lant prophylaxis.
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